Knowing that antihormone therapies and inhibitors of EGFR/HER2 are already used for therapy of breast cancer [93, 94], we propose that patients diagnosed with high TNFα, estrogen, and EGF levels would benefit from targeting all three arms simultaneously and that clinicians should consider the possibility of treating such patients with a cocktail of all three modalities: TNFα inhibitors + antihormonal therapies + inhibitors of EGFR/HER2. This evidence concerns the gene EGF and breast cancer.